期刊
MACROMOLECULAR BIOSCIENCE
卷 16, 期 8, 页码 1239-1249出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/mabi.201600035
关键词
biodegradable; nanomedicine; platinum(IV) prodrugs; polymer therapeutics; polyphosphazenes
资金
- Austrian Science Fund (FWF) [P24659-N28]
- COST action [CM1105]
- [P26603]
- Austrian Science Fund (FWF) [P 24659] Funding Source: researchfish
- Austrian Science Fund (FWF) [P24659] Funding Source: Austrian Science Fund (FWF)
The preparation of novel macromolecular prodrugs via the conjugation of two platinum(IV) complexes to suitably functionalized poly(organo)phosphazenes is presented. The inorganic/organic polymers provide carriers with controlled dimensions due to the use of living cationic polymerization and allow the preparation of conjugates with excellent aqueous solubility but long-term hydrolytic degradability. The macromolecular Pt(IV) prodrugs are designed to undergo intracellular reduction and simultaneous release from the macromolecular carrier to present the active Pt(II) drug derivatives. In vitro investigations show a significantly enhanced intracellular uptake of Pt for the macromolecular prodrugs when compared to small molecule Pt complexes, which is also reflected in an increase in cytotoxicity. Interestingly, drug-resistant sublines also show a significantly smaller resistance against the conjugates compared to clinically established platinum drugs, indicating that an alternative uptake route of the Pt(IV) conjugates might also be able to overcome acquired resistance against Pt(II) drugs. In vivo studies of a selected conjugate show improved tumor shrinkage compared to the respective Pt(IV) complex.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据